In addition, the combination of the neoantigen nanovaccine and anti-PD1 antibody or Treg inhibiting peptide P60 can further enhance the tumor inhibition effect, providing a feasible combination strategy for tumor immunotherapy. Here, PDCD1 is linked to neoplasm.